BR112015024060A2 - composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto - Google Patents
composto, composição farmacêutica, método para o tratamento de doenças e uso de um compostoInfo
- Publication number
- BR112015024060A2 BR112015024060A2 BR112015024060A BR112015024060A BR112015024060A2 BR 112015024060 A2 BR112015024060 A2 BR 112015024060A2 BR 112015024060 A BR112015024060 A BR 112015024060A BR 112015024060 A BR112015024060 A BR 112015024060A BR 112015024060 A2 BR112015024060 A2 BR 112015024060A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treating diseases
- formula
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2013/000639 WO2014147636A1 (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| IN1199CH2013 IN2013CH01199A (https=) | 2013-03-20 | 2013-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015024060A2 true BR112015024060A2 (pt) | 2017-07-18 |
Family
ID=54325095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024060A BR112015024060A2 (pt) | 2013-03-20 | 2013-10-18 | composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9790211B2 (https=) |
| EP (1) | EP2976337B1 (https=) |
| JP (1) | JP6185650B2 (https=) |
| KR (1) | KR101815307B1 (https=) |
| CN (1) | CN105164119B (https=) |
| AP (1) | AP2015008742A0 (https=) |
| AU (1) | AU2013382944B2 (https=) |
| BR (1) | BR112015024060A2 (https=) |
| CA (1) | CA2907620C (https=) |
| DK (1) | DK2976337T3 (https=) |
| EA (1) | EA029365B1 (https=) |
| ES (1) | ES2674993T3 (https=) |
| IN (1) | IN2013CH01199A (https=) |
| MX (1) | MX364929B (https=) |
| NZ (1) | NZ712369A (https=) |
| SG (1) | SG11201507763RA (https=) |
| WO (1) | WO2014147636A1 (https=) |
| ZA (1) | ZA201506804B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3265459B1 (en) * | 2015-02-13 | 2019-05-15 | Suven Life Sciences Limited | Amide compounds as 5-ht4 receptor agonists |
| CN109444301A (zh) * | 2018-12-18 | 2019-03-08 | 江苏省中医院 | 一种测定血浆中普芦卡必利浓度的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5150393A (en) * | 1992-10-13 | 1994-05-09 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
| NZ257545A (en) | 1992-11-05 | 1997-01-29 | Smithkline Beecham Plc | Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions |
| FR2756564B1 (fr) * | 1996-12-04 | 2004-05-14 | Synthelabo | Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique |
| AU2001225664A1 (en) * | 2000-06-15 | 2001-12-24 | Respiratorius Ab | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction |
| EA010630B1 (ru) | 2003-06-19 | 2008-10-30 | Янссен Фармацевтика Н.В. | 4-(аминометил) пиперидинбензамиды, обладающие 5нт-антагонистической активностью |
| BRPI0416813A (pt) | 2003-11-24 | 2007-03-06 | Pfizer | compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4 |
| JP4740152B2 (ja) * | 2003-12-23 | 2011-08-03 | セロドス アクスイェ セルスカブ | 末梢性5−ht受容体の修飾因子 |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| EP1856114B1 (en) | 2005-02-25 | 2014-08-20 | Pfizer Inc. | Benzisoxazole derivatives |
| US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
| GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| JP6023926B2 (ja) * | 2010-02-12 | 2016-11-09 | 株式会社AskAt | 認知症治療のための5−ht4受容体アゴニスト |
| MX2012008721A (es) | 2010-02-16 | 2012-08-17 | Pfizer | (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4. |
-
2013
- 2013-10-18 ES ES13811624.9T patent/ES2674993T3/es active Active
- 2013-10-18 BR BR112015024060A patent/BR112015024060A2/pt not_active IP Right Cessation
- 2013-10-18 NZ NZ712369A patent/NZ712369A/en not_active IP Right Cessation
- 2013-10-18 AP AP2015008742A patent/AP2015008742A0/xx unknown
- 2013-10-18 AU AU2013382944A patent/AU2013382944B2/en not_active Ceased
- 2013-10-18 JP JP2016504852A patent/JP6185650B2/ja not_active Expired - Fee Related
- 2013-10-18 CN CN201380074877.9A patent/CN105164119B/zh not_active Expired - Fee Related
- 2013-10-18 WO PCT/IN2013/000639 patent/WO2014147636A1/en not_active Ceased
- 2013-10-18 US US14/777,925 patent/US9790211B2/en not_active Expired - Fee Related
- 2013-10-18 SG SG11201507763RA patent/SG11201507763RA/en unknown
- 2013-10-18 DK DK13811624.9T patent/DK2976337T3/en active
- 2013-10-18 IN IN1199CH2013 patent/IN2013CH01199A/en unknown
- 2013-10-18 MX MX2015012350A patent/MX364929B/es active IP Right Grant
- 2013-10-18 KR KR1020157030158A patent/KR101815307B1/ko not_active Expired - Fee Related
- 2013-10-18 EA EA201591844A patent/EA029365B1/ru not_active IP Right Cessation
- 2013-10-18 CA CA2907620A patent/CA2907620C/en not_active Expired - Fee Related
- 2013-10-18 EP EP13811624.9A patent/EP2976337B1/en active Active
-
2015
- 2015-09-14 ZA ZA2015/06804A patent/ZA201506804B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101815307B1 (ko) | 2018-01-04 |
| JP2016516089A (ja) | 2016-06-02 |
| ES2674993T3 (es) | 2018-07-05 |
| US9790211B2 (en) | 2017-10-17 |
| DK2976337T3 (en) | 2018-07-16 |
| EA201591844A1 (ru) | 2016-08-31 |
| EP2976337A1 (en) | 2016-01-27 |
| WO2014147636A8 (en) | 2014-12-04 |
| AP2015008742A0 (en) | 2015-09-30 |
| EA029365B1 (ru) | 2018-03-30 |
| JP6185650B2 (ja) | 2017-08-23 |
| EP2976337B1 (en) | 2018-05-02 |
| WO2014147636A1 (en) | 2014-09-25 |
| CN105164119B (zh) | 2017-12-08 |
| ZA201506804B (en) | 2016-07-27 |
| AU2013382944B2 (en) | 2016-08-04 |
| US20160280694A1 (en) | 2016-09-29 |
| MX364929B (es) | 2019-05-14 |
| AU2013382944A1 (en) | 2015-10-08 |
| CA2907620C (en) | 2018-03-13 |
| NZ712369A (en) | 2016-11-25 |
| SG11201507763RA (en) | 2015-10-29 |
| MX2015012350A (es) | 2016-05-09 |
| CA2907620A1 (en) | 2014-09-25 |
| HK1217483A1 (zh) | 2017-01-13 |
| CN105164119A (zh) | 2015-12-16 |
| KR20160004274A (ko) | 2016-01-12 |
| IN2013CH01199A (https=) | 2015-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| BR112015017997A8 (pt) | amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
| EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201591339A1 (ru) | Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| EA201690888A1 (ru) | Новые гетероциклические соединения | |
| BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |